MedTrace Logo

Evaluation of the Efficacy of a Food Supplement in Reducing Hair Loss in Male Subjects

NCT04884347 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-05-13

No results posted yet for this study

Summary

According to the American Hair Loss Association, by the age of 35, two-thirds of American men will have some degree of appreciable hair loss, and by the age of 50, approximately 50 to 85% of men will have significant hair thinning.

Hair is an essential aspect of human appearance and can have a significant impact on a person's self-esteem, mood and quality of life. Unfortunately, current treatment options can be costly, tedious or painful. They are also associated with numerous side effects.

Here, the investigators aimed at evaluating the effect of a new food supplement on hair condition in young men suffering from hair loss. A second goal was to determine tolerability.

Conditions

Interventions

DIETARY_SUPPLEMENT

Alline proMEN

1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months

DIETARY_SUPPLEMENT

Placebo

1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months

Sponsors & Collaborators

  • Complife Italia S.r.l

    collaborator UNKNOWN

  • Università degli Studi di Pavia

    collaborator UNKNOWN

  • Laboratoires Pharmaceutiques Trenker

    lead INDUSTRY

Principal Investigators

  • Vincenzo Nobile, PhD · Complife Italia S.r.l

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-31
Primary Completion
2021-02-04
Completion
2021-02-04

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04884347 on ClinicalTrials.gov